anti-ANGPTL4 (human), mAb (Kairos-1)

Product description: ANGPTL4 mainly expressed in endothelial cells (hypoxia-induced). Regulates angiogenesis and modulates tumorgenesis and directly regulates lipid, glucose, and energy metabolism. Inhibits proliferation, migration, and tubule formation of endothelial cells and reduces vascular leakage. ANGPTL4 is a protein consisting of an N-terminal coiled-coil domain and a C-terminal fibrinogen-like domain (FLD). Both domains have distinct biological functions. The coiled-coil domain is responsible for the inhibitory effects on lipoprotein lipase (LPL) converting the active form of LPL into an inactive form, and the FLD domain mediates its antiangiogenic functions. The coiled coil and the FLD domains are separated by a short linker that can be cleaved after secretion. ANGPTL4 appears on the cell surface as the full-length form, where it can be released by heparin treatment. ANGPTL4 protein is then proteolytically cleaved by proprotein convertases (PCs), including furin, PC5/6, paired basic amino acid-cleaving enzyme 4, and PC7.

Alternate Names/Synonyms: Angiopoietin-like Protein 4; FIAF; Fasting-induced Adipose Factor; HFARP; Hepatic Fibrinogen/Angiopoietin-related Protein

Product Type: Monoclonal Antibody

Clone: Kairos-1

Isotype: Mouse IgG1kappa

Immunogen: Recombinant human ANGPTL4.

Applications: ELISA, IHC, WB

Species Crossreactivity: Human

Specificity: Recognizes the fibrinogen-like domain (FLD) of human ANGPTL4. Detects a band of ~62kDa and ~35kDa by Western blot. Does not cross-react with other ANGPTL family proteins.

Concentration: 1mg/ml

Short Term Storage: +4°C

Long Term Storage: -20°C

Shipping: BLUE ICE

Use & Stability: Stable for at least 1 year after receipt when stored at -20°C.

Lien vers la Fiche Technique